Gene Therapy for GA: ArMaDa Trial Update

Show Description +

Dr. Maturi highlights key takeaways from the phase 2 ArMaDa trial of OCU410 (Ocugen), a modifier gene therapy for GA. The 12-month topline safety and efficacy data show positive findings with the medium dose, which is moving into phase 3 trials.

Posted: 10/15/2026

Keywords:

Clinical Trials

•

ArMaDa

•

OCU410

•

Ocugen

•

Gene Therapy

•

Geographic Atrophy (GA)

•

retina-meeting-recap

•

Retina Subspecialty Day

Up Next

Name: Gene Therapy for GA: ArMaDa Trial Update
Uploaded: 2026-10-15T19:25:08+00:00
Description: Dr. Maturi highlights key takeaways from the phase 2 ArMaDa trial of OCU410 (Ocugen), a modifier gene therapy for GA. The 12-month topline safety and efficacy data show positive findings with the medium dose, which is moving into phase 3 trials.

An Ophthalmologist’s Evolving Collaboration With Neurosurgery

Kyle J. Godfrey, MD, FACS

Highlights From This Year’s Cornea Literature

Divya Srikumaran, MD

Considerations for Monovision and Mini-Monovision Approaches

Nandini Venkateswaran, MD

$Exploring the Frontiers of Refractive Surgery$

Exploring the Frontiers of Refractive Surgery

Julie Schallhorn, MD, MS

Customized CAIRS for Post-LASIK Ectasia

Soosan Jacob, MD

Three Lessons for Glaucoma Graduates

David Fleischman, MD, MS, FACS

Taking the Leap Toward VR Perimetry

Matthew Brink, MD

Reliable IOP Measurements With the iCare Tonometer

Sanjay Asrani, MD

High-Tech Solutions for Low Vison

Sharon Fekrat, MD, FACS

The Gene Therapy Pipeline for AMD

Allen C. Ho, MD

First-Time Phase 2 Data for Sura-Vec in DME

Arshad M. Khanani, MD

Repairing TRDs in the Retina OR

Maria H. Berrocal, MD

Complement Inhibitors in Practice: Longer-Term Findings

Sunir J. Garg, MD, FACS

Sickle Cell Retinopathy: An Update on Screening and Care

Adrienne Williams Scott, MD

Novel Approaches to Measuring GA Progression

SriniVas R. Sadda, MD

Positive Phase 3 Data for Tarcocimab

Charles C. Wykoff, MD, PhD

Inflammasome Inhibitor Moving Through the Pipeline

Liangbo Linus Shen, MD

Pivotal Data For the Treatement of XLRP

Robert A. Sisk MD

Gene Therapy for GA: ArMaDa Trial Update

Raj K. Maturi, MD

Back to All Videos

Gene Therapy for GA: ArMaDa Trial Update

Raj K. Maturi, MD

Posted: 10/15/2026

Keywords:

Clinical Trials

•

ArMaDa

•

OCU410

•

Ocugen

•

Gene Therapy

•

Geographic Atrophy (GA)

•

retina-meeting-recap

•

Retina Subspecialty Day

Read Transcript

Yesterday I presented at Retina Subspecialty Day for the first time phase two results of IQ410. It's a one-time subretinal gene therapy for dry macular degeneration. These were a small study done on 51 subjects, 17 in a control group, 17 in a high dose, and 17 in a medium dose. We found that the medium dose had relatively good and positive results. We showed, for example, that there was almost a 30% decline in growth of the DDAF in the medium dose compared to the control group. The high dose didn't do that well. We also showed consistent with the decrease in DDAF, we showed that on OCT, the RPE loss and EZ loss decreased with treatment. Based on the strong results of this study, IQ410 at the medium dose is now going to go on to a phase three study. This study has already started enrollment. I'm truly looking forward to a one-time gene therapy as opposed to monthly injections for my patients with geographic atrophy.

Thank you for your time.

Please log in to leave a comment.

Meeting Coverage:

American Academy of Ophthalmology

Gene Therapy for GA: ArMaDa Trial Update

Up Next

Gene Therapy for GA: ArMaDa Trial Update

More From AAO: 2026 Coverage